Lexeo Therapeutics Files 8-K on Financials
Ticker: LXEO · Form: 8-K · Filed: Mar 24, 2025 · CIK: 1907108
| Field | Detail |
|---|---|
| Company | Lexeo Therapeutics, Inc. (LXEO) |
| Form Type | 8-K |
| Filed Date | Mar 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, disclosure
Related Tickers: LXEO
TL;DR
Lexeo Therapeutics (LXEO) filed an 8-K on 3/24/25 detailing financial condition and results of operations.
AI Summary
Lexeo Therapeutics, Inc. filed an 8-K on March 24, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 345 Park Avenue South, Floor 6, New York, NY 10010. Lexeo Therapeutics is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This 8-K filing provides an update on Lexeo Therapeutics' financial status and operational results, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate material adverse events.
Key Players & Entities
- Lexeo Therapeutics, Inc. (company) — Registrant
- March 24, 2025 (date) — Date of earliest event reported
- 345 Park Avenue South, Floor 6, New York, NY 10010 (location) — Address of Principal Executive Offices
- Delaware (jurisdiction) — State of Incorporation
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on March 24, 2025.
What is the primary business of Lexeo Therapeutics, Inc. according to the filing?
Lexeo Therapeutics, Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code [2836].
Where are Lexeo Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 345 Park Avenue South, Floor 6, New York, New York 10010.
What is the Commission File Number for Lexeo Therapeutics, Inc.?
The Commission File Number is 001-41855.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 24, 2025 regarding Lexeo Therapeutics, Inc. (LXEO).